ライフサイエンスコーパス: amyloid beta-protein

1 s effect is exacerbated with the addition of amyloid beta protein.

2 ole in Alzheimer's disease by generating the amyloid beta protein.

3 d by diffusible oligomeric assemblies of the amyloid beta protein.

4 (LVFFAEDVGSNK), a tryptic fragment from the amyloid beta-protein.

5 ipoprotein E4, amyloid precursor protein and amyloid beta-protein.

6 mbrane protein involved in the production of amyloid beta-protein.

7 aved products, Notch intracellular domain or amyloid-beta protein.

8 ys by which hypoperfusion influenced tau and amyloid-beta proteins.

9 rval: 0.64-0.83) and for cerebrospinal fluid amyloid beta protein 1-42 was 0.685 (95% confidence inte

10 an score 7.6 +/- 5.3 for cerebrospinal fluid amyloid beta protein 1-42).

11 nergy landscapes and relative stabilities of amyloid-beta protein (1-40) in the monomer and all of it

12 abilities of amyloid-beta protein (1-42) and amyloid-beta protein (1-40) in their monomeric and oligo

13 nergy landscapes and relative stabilities of amyloid-beta protein (1-42) and amyloid-beta protein (1-

14 Amyloid beta protein (A beta) accumulates in the brains

15 The deposition of amyloid beta-protein (A beta or beta A4) is a key featur

16 ogical folding and oligomer formation of the amyloid beta-protein (A beta) are widely perceived as ce

17 Assembly of monomeric amyloid beta-protein (A beta) into oligomeric structures

18 Cerebral deposition of amyloid beta-protein (A beta) is believed to play a key

19 Amyloid beta-protein (A beta) is the main constituent of

20 the beta- and gamma-secretases generate the amyloid beta-protein (A beta), which plays a central rol

21 The accumulation of fibrillar amyloid-beta protein (A beta) in cerebral blood vessels,

22 ing soluble aggregation intermediates of the amyloid-beta protein (A beta), as well as the ongoing gr

23 e 1 transmembrane protein, gives rise to the amyloid beta-protein, a neurotoxic peptide postulated to

24 Accumulation of amyloid beta protein (Abeta) aggregates is hypothesized

25 ng the deposition of amyloidogenic proteins, amyloid beta protein (Abeta) and amylin (islet amyloid p

26 ers involved in Alzheimer's disease (AD) are amyloid beta protein (Abeta) and apolipoprotein E (apoE)

27 Interaction between aggregates of amyloid beta protein (Abeta) and membranes has been hypo

28 Direct immunization with amyloid beta protein (Abeta) and passive transfer of ant

29 Cerebral microvascular amyloid beta protein (Abeta) deposition and associated n

30 Amyloid beta protein (Abeta) deposition in the brain is

31 (APP695SWE) develop Alzheimer's disease-like amyloid beta protein (Abeta) deposits by 8 to 10 months

32 e progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, ora

33 e data support a central pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, the

34 acterized by the progressive accumulation of amyloid beta protein (Abeta) in areas of the brain servi

35 the progressive deposition of the 42-residue amyloid beta protein (Abeta) in brain regions serving me

36 uction and clearance of the self-aggregating amyloid beta protein (Abeta) in brain regions serving me

37 s characterised in part by the deposition of amyloid beta protein (Abeta) in the brain.

38 The accumulation of amyloid beta protein (Abeta) in the Tg2576 mouse model o

39 (AD) maintains that the accumulation of the amyloid beta protein (Abeta) is a critical event in dise

40 The aggregation of amyloid beta protein (Abeta) is a fundamental pathogenic

41 odents suggest that soluble oligomers of the amyloid beta protein (Abeta) may discretely interfere wi

42 The aggregation of monomeric amyloid beta protein (Abeta) peptide into oligomers and

43 ic hallmarks of Alzheimer's disease (AD) are amyloid beta protein (Abeta) plaques and neurofibrillary

44 indings suggest that oligomeric forms of the amyloid beta protein (Abeta) play a critical role in Alz

45 APP at minor Asp(1) site to generate C99 for amyloid beta protein (Abeta) production, and predominant

46 Deposition of amyloid beta protein (Abeta) to form neuritic plaques in

47 en developed to study the pathophysiology of amyloid beta protein (Abeta) toxicity, which is thought

48 Amyloid beta protein (Abeta), a relevant risk factor in

49 heimer's disease (AD) is the accumulation of amyloid beta protein (Abeta), a small peptide derived fr

50 Cerebral deposition of the amyloid beta protein (Abeta), an invariant feature of Al

51 is associated with elevated brain levels of amyloid beta protein (Abeta), particularly neurotoxic Ab

52 Amyloid beta protein (Abeta), the principal component of

53 rated that the TNFR1 cascade is required for amyloid beta protein (Abeta)-induced neuronal death.

54 of tau appears to be a downstream effect of amyloid beta protein (Abeta).

55 ive stress and the accumulation of fibrillar amyloid beta proteins (Abeta) in senile plaques througho

56 Amyloid fibrils, large ordered aggregates of amyloid beta proteins (Abeta), are clinical hallmarks of

57 c differences in structural dynamics between amyloid beta-protein (Abeta) 40 and Abeta42 appear to un

58 The C-terminus of amyloid beta-protein (Abeta) 42 plays an important role

59 ubstrates of insulin-degrading enzyme (IDE), amyloid beta-protein (Abeta) and insulin, are critically

60 urther cleaved by gamma-secretase to produce amyloid beta-protein (Abeta) and p3, respectively.

61 Increased production and deposition of amyloid beta-protein (Abeta) are believed to be key path

62 Proteases that degrade the amyloid beta-protein (Abeta) are important regulators of

63 Oligomeric forms of amyloid beta-protein (Abeta) are key neurotoxins in Alzh

64 e to suggest that ABri and the AD-associated amyloid beta-protein (Abeta) are molecular equivalents t

65 Amyloid beta-protein (Abeta) assembly into toxic oligome

66 easing evidence supports the hypothesis that amyloid beta-protein (Abeta) assembly is a key pathogeni

67 Amyloid beta-protein (Abeta) assembly is hypothesized to

68 Cerebral vascular amyloid beta-protein (Abeta) deposition, also known as c

69 Amyloid beta-protein (Abeta) fibril assembly is a defini

70 ved by Lowe et al. to simultaneously enhance amyloid beta-protein (Abeta) fibrillogenesis and decreas

71 The deposition of amyloid beta-protein (Abeta) fibrils into plaques within

72 hioflavin T associated with freshly extended amyloid beta-protein (Abeta) fibrils.

73 In Alzheimer's disease (AD), the amyloid beta-protein (Abeta) forms neurotoxic oligomers.

74 cts of isoflurane on apoptosis are linked to amyloid beta-protein (Abeta) generation and aggregation.

75 loid precursor protein (APP) processing, and amyloid beta-protein (Abeta) generation in H4 human neur

76 the structural and assembly dynamics of the amyloid beta-protein (Abeta) has direct relevance to the

77 Oligomeric assemblies of the amyloid beta-protein (Abeta) have been implicated in the

78 esenilin 1 (PS1) decreases the production of amyloid beta-protein (Abeta) identified the presenilins

79 e suggests that the accumulation of cerebral amyloid beta-protein (Abeta) in Alzheimer's disease (AD)

80 The assembly and deposition of amyloid beta-protein (Abeta) in brain is a key pathologi

81 ntia that involves progressive deposition of amyloid beta-protein (Abeta) in brain regions important

82 The accumulation of amyloid beta-protein (Abeta) in brain regions serving me

83 ggregation of Alzheimer's disease-associated amyloid beta-protein (Abeta) in cultured cells.

84 The causes of cerebral accumulation of amyloid beta-protein (Abeta) in most cases of Alzheimer'

85 Deposits of amyloid beta-protein (Abeta) in neuritic plaques and cer

86 Accumulation of amyloid beta-protein (Abeta) in neurons has been demonst

87 Deposition of fibrillar amyloid beta-protein (Abeta) in the brain is a prominent

88 ed ACE has been reported to cleave synthetic amyloid beta-protein (Abeta) in vitro.

89 We have recently reported that fibrillar amyloid beta-protein (Abeta) inhibits the proteolytic ac

90 Accumulation of amyloid beta-protein (Abeta) into brain parenchymal plaq

91 Assembly of the amyloid beta-protein (Abeta) into neurotoxic oligomers a

92 ests that the folding and aggregation of the amyloid beta-protein (Abeta) into oligomers is a key pat

93 Cerebrovascular deposition of amyloid beta-protein (Abeta) is a common pathological fe

94 Oligomerization of the amyloid beta-protein (Abeta) is a seminal event in Alzhe

95 The amyloid beta-protein (Abeta) is a seminal neuropathic ag

96 Progressive cerebral accumulation of amyloid beta-protein (Abeta) is an early and invariant f

97 Amyloid beta-protein (Abeta) is central to the pathology

98 cture of the 21-30 fragment of the Alzheimer amyloid beta-protein (Abeta) is investigated by replica-

99 (gamma-secretase) that cleave APP to release amyloid beta-protein (Abeta) is likely to be presenilin.

100 c oligomeric and fibrillar structures by the amyloid beta-protein (Abeta) is linked to Alzheimer's di

101 Amyloid beta-protein (Abeta) is linked to neuronal injur

102 Amyloid beta-protein (Abeta) is present in soluble form

103 ented LTP inhibition by soluble oligomers of amyloid beta-protein (Abeta) isolated from AD cortex.

104 port on the plasticity-disrupting effects of amyloid beta-protein (Abeta) isolated from Alzheimer's d

105 (AD) is age-dependent, brain accumulation of amyloid beta-protein (Abeta) leading to Abeta self-assoc

106 Amyloid beta-protein (Abeta) molecules tend to aggregate

107 Using Tg2576 mice, which model AD-type amyloid beta-protein (Abeta) neuropathology, we tested w

108 The final proteolytic step to generate the amyloid beta-protein (Abeta) of Alzheimer's disease (AD)

109 The roles of metal ions in promoting amyloid beta-protein (Abeta) oligomerization associated

110 Strong evidence exists for a central role of amyloid beta-protein (Abeta) oligomers in the pathogenes

111 Amyloid beta-protein (Abeta) oligomers may be the proxim

112 assay using antibodies that are specific for amyloid beta-protein (Abeta) oligomers with sub-femtomol

113 Soluble amyloid beta-protein (Abeta) oligomers, the main neuroto

114 Oligomers of amyloid beta-protein (Abeta) play a central role in the

115 evidence suggests that soluble assemblies of amyloid beta-protein (Abeta) play an important role in t

116 The 40-42 residue amyloid beta-protein (Abeta) plays a central role in the

117 treating Alzheimer's disease (AD), in which amyloid beta-protein (Abeta) plays a key pathogenic role

118 many type I membrane proteins, including the amyloid beta-protein (Abeta) precursor (APP) and the Not

119 many type I membrane proteins, including the amyloid beta-protein (Abeta) precursor (APP) and the Not

120 Mutations in the amyloid beta-protein (Abeta) precursor gene cause autoso

121 In Alzheimer's disease (AD), amyloid beta-protein (Abeta) self-assembles into toxic o

122 Amyloid beta-protein (Abeta) self-assembly is linked str

123 One of the earliest events in amyloid beta-protein (Abeta) self-association is nucleat

124 Amyloid beta-protein (Abeta) sequence length variants wi

125 We used amyloid beta-protein (Abeta) to further explore the bind

126 euronal cell surface receptor that regulates amyloid beta-protein (Abeta) trafficking into the cell.

127 Until recently, naturally occurring amyloid beta-protein (Abeta) variants were believed to b

128 Cerebrovascular accumulation of amyloid beta-protein (Abeta), a condition known as cereb

129 gamma-Secretase generates amyloid beta-protein (Abeta), a pathogenic molecule in A

130 that oligomers of the 42-residue form of the amyloid beta-protein (Abeta), Abeta42, play a critical r

131 Amyloid plaques, composed of the amyloid beta-protein (Abeta), are hallmark neuropatholog

132 TP) can be inhibited by soluble oligomers of amyloid beta-protein (Abeta), but the synaptic elements

133 in Alzheimer's disease, soluble oligomers of amyloid beta-protein (Abeta), have been complicated by t

134 IDE) in mice causes accumulation of cerebral amyloid beta-protein (Abeta), hyperinsulinemia, and gluc

135 hat a small amphipathic fragment of APP, the amyloid beta-protein (Abeta), self-associates to form so

136 APP is the precursor to the amyloid beta-protein (Abeta), the 38-43-amino acid resid

137 Amyloid beta-protein (Abeta), the major component of cer

138 Numerous studies have now shown that the amyloid beta-protein (Abeta), the principal component of

139 the amyloid precursor protein (APP) produces amyloid beta-protein (Abeta), the probable causative age

140 ave been examined primarily as inhibitors of amyloid beta-protein (Abeta), whereas testing of inhibit

141 The amyloid beta-protein (Abeta), which accumulates abnormal

142 Importantly, amyloid beta-protein (Abeta)-induced neuronal compromise

143 relevant peptides, including insulin and the amyloid beta-protein (Abeta).

144 his association may impact the production of amyloid beta-protein (Abeta).

145 ated with formation of fibrillar deposits of amyloid beta-protein (Abeta).

146 f synaptic plasticity by Alzheimer's disease amyloid beta-protein (Abeta).

147 eta40 are the two primary alloforms of human amyloid beta-protein (Abeta).

148 se (AD) contain large deposits of aggregated amyloid beta-protein (Abeta).

149 imate pathologic agents are oligomers of the amyloid beta-protein (Abeta).

150 D) is linked to the aberrant assembly of the amyloid beta-protein (Abeta).

151 id fibrils formed from long fragments of the amyloid beta-protein (Abeta-protein), the monomers are a

152 Insoluble fibrillar plaques of amyloid beta-proteins (Abeta) and neurofibrillary deposi

153 neurodegeneration associated with deposited amyloid-beta protein (Abeta) aggregates in the brains of

154 While amyloid-beta protein (Abeta) aggregation into insoluble

155 cides with the accumulation of extracellular amyloid-beta protein (Abeta) and intraneuronal tau aggre

156 ctive in inducing an immune response against amyloid-beta protein (Abeta) and reducing brain Abeta lo

157 Brain accumulation of the amyloid-beta protein (Abeta) and synapse loss are neurop

158 dies have determined that fibrillar forms of amyloid-beta protein (Abeta) comprise the characteristic

159 loid hypothesis suggests that the process of amyloid-beta protein (Abeta) fibrillogenesis is responsi

160 myloid precursor protein (APP), and increase amyloid-beta protein (Abeta) generation.

161 ggests water-soluble, non-fibrillar forms of amyloid-beta protein (Abeta) have important roles in Alz

162 able evidence supports a causal role for the amyloid-beta protein (Abeta) in AD, a direct link betwee

163 Deposition of fibrillar amyloid-beta protein (Abeta) in senile plaques and in th

164 The aggregation of amyloid-beta protein (Abeta) in vivo is a critical patho

165 The oligomerization of the amyloid-beta protein (Abeta) is an important event in Al

166 Amyloid-beta protein (Abeta) is thought to play an impor

167 We extracted soluble amyloid-beta protein (Abeta) oligomers directly from the

168 Specific mutations within the amyloid-beta protein (Abeta) peptide have been identifie

169 protein (APP) and its pathogenic by-product amyloid-beta protein (Abeta) play central roles in Alzhe

170 that interaction of CypD with mitochondrial amyloid-beta protein (Abeta) potentiates mitochondrial,

171 The amyloid-beta protein (Abeta) protein plays a pivotal rol

172 de hypothesis," linking self-assembly of the amyloid-beta protein (Abeta) to the pathogenesis of Alzh

173 Here, we show that amyloid-beta protein (Abeta), a major component of plaqu

174 The final step in the generation of the amyloid-beta protein (Abeta), implicated in the etiology

175 croglia are activated by aggregated forms of amyloid-beta protein (Abeta), usually demonstrated in vi

176 generate various polypeptides, including the amyloid-beta protein (Abeta), which forms amyloid plaque

177 amma-secretases results in generation of the amyloid-beta protein (Abeta), which is characteristicall

178 cumulation of amyloid plaques containing the amyloid-beta protein (Abeta).

179 ociated with pathological assembly states of amyloid-beta protein (Abeta).

180 The amount of amyloid beta protein, Abeta(42(43)), but not Abeta(40,)

181 (ELISA) to measure plasma concentrations of amyloid beta proteins Abeta40 and Abeta42 among 55 adult

182 brils formed by the Arctic variant (E22G) of amyloid-beta protein (Abeta40(ARC)) as well as the effec

183 however, it is the shorter and more soluble amyloid beta protein, Abeta40, that predominates.

184 lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line.

185 Plasma amyloid beta protein (Abeta42) levels and late onset Alz

186 Using plasma amyloid beta protein (Abeta42) levels as an intermediate

187 Amyloid beta protein (AbetaP) is the major constituent o

188 Here, we show that soluble amyloid beta protein accelerates amyloid precursor prote

189 h with CLR01 resulted in a decrease in brain amyloid beta protein aggregates, hyperphosphorylated tau

190 lyphenolic extract can significantly inhibit amyloid beta-protein aggregation into high-molecular-wei

191 d which is used as a surrogate marker of non-amyloid-beta protein aggregation.

192 embly of the two predominant disease-related amyloid beta-protein alloforms, Abeta40 and Abeta42.

193 cline in the absence of neurodegeneration or amyloid-beta protein amyloidosis.

194 oteins including TAR DNA-binding protein 43, amyloid beta protein and alpha-synuclein.

195 f multiple amyloidogenic proteins, including amyloid beta protein and tau, by disrupting key interact

196 caused by toxic oligomers and aggregates of amyloid beta protein and the microtubule-associated prot

197 anes are known to promote the aggregation of amyloid beta proteins and fibril formation.

198 ecursor protein (APP) processing and affects amyloid beta-protein and APP secretion and APP-c-termina

199 longitudinal MRI; (iii) post-mortem regional amyloid-beta protein and tau associated neurofibrillary

200 opment of in vivo imaging probes targeted to amyloid beta protein, and one agent is already available

201 id membranes promote beta-sheet formation by amyloid beta-proteins, and they suggest a possible role

202 Cerebral amyloid beta-protein angiopathy (CAA) is a key pathologi

203 Although the amyloid-beta protein associated with the Alzheimer's dis

204 eurons are defective in apoptosis induced by amyloid-beta protein but not by staurosporine or trophic

205 how that BSB binds not only to extracellular amyloid beta protein, but also many intracellular lesion

206 The aggregation properties of amyloid beta proteins can be strongly affected by single

207 glish and the Tottori, the mutations produce amyloid beta-proteins containing amino acid substitution

208 or protein may be another mechanism by which amyloid beta protein contributes to synapse loss and neu

209 ent transgenic mouse models suggest that the amyloid beta-protein contributes to memory loss in Alzhe

210 In vivo, the levels of soluble amyloid beta protein correlated with caspase-cleaved fra

211 n of angiotensin-converting enzyme (ACE), an amyloid-beta protein degrading enzyme, to brain resident

212 ectron microscopy in a preparation of seeded amyloid beta protein fibrils that formed at relatively l

213 ion of peptide self-assembly pathways in the amyloid-beta protein fragment Abeta(25-35) by two amyloi

214 s, such as angiotensin I (Agt I) and [Gln11]-amyloid-beta-protein fragment 1-16 (A beta(1-16)), the o

215 ce gamma-secretase can specifically generate amyloid beta-protein from an APP substrate and similarly

216 Progressive accumulation of the amyloid beta protein in extracellular plaques is a neuro

217 in the islet and brain (amyloid derived from amyloid beta protein in the brain in Alzheimer disease a

218 Moreover, levels of amyloid beta protein in the brains of treated mice did n

219 as potential contributory factors, including amyloid beta-protein in Alzheimer's disease, tau in fron

220 hemical basis for oxidative damage caused by amyloid-beta protein in AD.

221 ntia, increase cell death, and deposition of amyloid-beta proteins in Alzheimer's disease brains.

222 ate early accumulation and spread of tau and amyloid-beta proteins in the pathological cascade of Alz

223 oxicity induced by the 42-residue isoform of amyloid beta protein, including approximately 80% inhibi

224 These findings suggest that soluble amyloid beta protein-induced multimerization of the amyl

225 ence that a defined molecular species of the amyloid-beta protein interferes with cognitive function.

226 haracterized by the self-assembly of tau and amyloid beta proteins into oligomers and fibrils.

227 The accumulation of amyloid-beta protein into plaques is a characteristic fe

228 Fragment 11-25 of the amyloid beta protein involved in Alzheimer's disease (Ab

229 dogenic effects of oxidative lipid damage on amyloid beta proteins is demonstrated and the mechanism

230 seed the formation of fibrils by unmodified amyloid beta proteins is enhanced.

231 gests that the aggregation and deposition of amyloid-beta protein is an initiating event in Alzheimer

232 We applied these methods to a number of the amyloid-beta protein isoforms of Abeta40 and Abeta42 and

233 etase cleavage of the mutant C99 to generate amyloid beta protein, leading to recessively inherited A

234 WT mice presented a significant increase in amyloid beta protein levels, a hallmark of AD.

235 in on learning and memory are independent of amyloid beta protein levels.

236 aptic preservation and reduction in cerebral amyloid-beta protein levels and astrogliosis (P < 0.001

237 airment and a 2-3-fold increase in insoluble amyloid-beta protein levels and deposition in the brain.

238 acellular amyloid deposits and intracellular amyloid beta protein may activate caspases, leading to c

239 nges, taken together with toxic insults from amyloid-beta protein, may underlie the observed neuronal

240 Oligomeric forms of amyloid beta protein (oAbeta) are believed to be princip

241 SIGNIFICANCE STATEMENT: Oligomers of amyloid beta-protein (oAbeta) are tought to play an impo

242 Soluble oligomers of amyloid beta-protein (oAbeta) isolated from the brains o

243 Elevated cerebral levels of amyloid beta-protein occur universally in Alzheimer's di

244 amma-secretase, critical to the formation of amyloid-beta protein, on membrane thickness and lipid co

245 rticularly vulnerable to early deposition of amyloid beta-protein, one of the hallmark pathologies of

246 However, for the amyloid beta-protein peptide (Abeta), thought to be the

247 ionship of APP-CTFgamma to the production of amyloid beta protein peptides is not known, we conclude

248 inal to the scissile bonds for production of amyloid beta protein peptides.

249 Processing of the amyloid beta protein precursor (A beta PP) by the beta a

250 he familial Alzheimer's disease gene product amyloid beta protein precursor (A beta PP) is sequential

251 Proteolytic processing of amyloid beta protein precursor (AbetaPP) generates pepti

252 ) is genetically linked to the processing of amyloid beta protein precursor (AbetaPP).

253 eta1-40 or Abeta1-42 in the absence of human amyloid beta protein precursor (APP) overexpression.

254 were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, an

255 en shown to influence limited proteolysis of amyloid beta protein precursor (APP), Notch and ErbB4, a

256 ease-causing mutations in the genes encoding amyloid beta protein precursor and presenilins, raising

257 d not affect the amyloidogenic processing of amyloid beta protein precursor.

258 ed increase in the levels of cell-associated amyloid beta-protein precursor (AbetaPP) and cell death.

259 The amyloid beta-protein precursor (AbetaPP) is best known a

260 The amyloid beta-protein precursor (AbetaPP) is best recogni

261 vidence suggests that dysregulated levels of amyloid beta-protein precursor (APP) and its catabolites

262 rous type I membrane proteins, including the amyloid beta-protein precursor (APP) and the Notch recep

263 se A beta is produced from the processing of amyloid beta-protein precursor (APP) by beta- and gamma-

264 Sequential cleavages of the amyloid beta-protein precursor (APP) by the beta- and ga

265 idation of the proteolytic processing of the amyloid beta-protein precursor (APP) has revealed that o

266 ated with Alzheimer disease, is derived from amyloid beta-protein precursor (APP) through sequential

267 es the amyloid beta-peptide (Abeta) from the amyloid beta-protein precursor (APP).

268 Both caspase-cleaved amyloid beta-protein precursor and activated caspase-9 w

269 nal presenilins and cleaves substrates (e.g. amyloid beta-protein precursor and Notch) with very loos

270 I integral membrane proteins, including the amyloid beta-protein precursor and the Notch receptor, a

271 I integral membrane proteins, including the amyloid beta-protein precursor and the Notch receptor.

272 ns of a variety of substrates, including the amyloid beta-protein precursor and the Notch receptor.

273 resses human vasculotropic Dutch/Iowa mutant amyloid beta-protein precursor in brain.

274 nd able to produce amyloid beta-peptides and amyloid beta-protein precursor intracellular domain.

275 is of a variety of substrates, including the amyloid beta-protein precursor of Alzheimer's disease an

276 al factor for optimal transcription from the amyloid beta-protein precursor promoter.

277 peptide inhibitors and designed to mimic the amyloid beta-protein precursor substrate bind specifical

278 ate the possibility that caspase cleavage of amyloid beta-protein precursor with the generation of C3

279 mice, an AD mouse model overexpressing human amyloid beta-protein precursor with the Swedish double m

280 agulant protein, an aprotinin mutant (6L15), amyloid beta-protein precursor, or tissue factor pathway

281 ical beta-secretase cleavage site within the amyloid beta-protein precursor.

282 The amyloid-beta protein precursor (AbetaPP) is a type I tra

283 own to attenuate amyloidogenic processing of amyloid-beta protein precursor (APP) in cell culture stu

284 P) binds to and regulates the translation of amyloid-beta protein precursor (App) mRNA, but the detai

285 Amyloid-beta protein precursor intracellular domain-asso

286 The amyloid-beta protein precursor, a type 1 transmembrane p

287 P cleaving enzyme 1 (BACE1) is essential for amyloid beta protein production.

288 99 amino acids, and measured the effects on amyloid-beta protein production and Notch signaling, res

289 Amyloid beta proteins spontaneously form fibrils in vitr

290 loid precursor protein to generate the toxic amyloid beta protein, the major component of plaques in

291 important to understand factors that induce amyloid beta-proteins to adopt this conformation.

292 ocytic receptor conferred protection against amyloid beta-protein toxicity in the presence of activat

293 y protects neurons from oxidative stress and amyloid beta-protein toxicity, and conditional deletion

294 th presenilin 1, increased susceptibility to amyloid beta-protein toxicity.

295 , also protects against oxidative stress and amyloid beta-protein toxicity.

296 The primary structure of canonical amyloid-beta-protein was elucidated more than 30 years a

297 se, lactate, pyruvate, glutamate and tau and amyloid-beta proteins, were measured every 1-2 h in the

298 2-nonenal modifies the three His residues in amyloid beta proteins, which increases their membrane af

299 ta-amyloid precursor protein (APP) generates amyloid beta-protein, which can assemble into oligomers

300 ease is a dense plaque composed of fibrillar amyloid beta-proteins with a characteristic and well-ord